MedTrace Logo

Specific Immunotherapy for Allergic Child

NCT02965612 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-11-17

No results posted yet for this study

Summary

The recent interest that the Specific Immunotherapy (ITS) has aroused is due to the positive potential role that could be played, in particular in the forms of allergic asthma, because this method constitute the only intervention (unlike that pharmacologic) able to act on the same causes of the disease, altering the natural history. To achieve this the investigator has tried to use the specific subcutaneous immunotherapy (SCIT), to which there are studies that, with scientific rigor, have demonstrated the benefits.

Conditions

  • Allergic Rhinitis
  • Allergic Asthma
  • Grass Allergy

Interventions

DEVICE

Injex

administration of Specific Immunotherapy (ITS) with car pressure injector without a needle

PROCEDURE

SCIT

administration of Specific Immunotherapy (ITS) via traditional subcutaneous

Sponsors & Collaborators

  • Bial Aristegui Italia srl

    collaborator UNKNOWN

  • OPBG Contract and Research Organization

    collaborator UNKNOWN

  • Mariella Enoc

    lead OTHER

Principal Investigators

  • Alessandro Fiocchi · Bambino Gesù Hospital and Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965612 on ClinicalTrials.gov